Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aripiprazole for schizophrenia.

H G El-Sayeh1, C Morganti

  • 1Harrogate District Hospital, Briary Wing, Lancaster Park Road, Harrogate, West Yorkshire, UK, HG2 7SX. hany.el-sayeh@chrd-pct.nhs.uk

The Cochrane Database of Systematic Reviews
|April 21, 2006
PubMed
Summary

Aripiprazole shows effectiveness in treating schizophrenia, reducing relapse rates and improving adherence compared to placebo. However, it offers limited advantages over other antipsychotics regarding overall efficacy and tolerability, though it may reduce specific side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of dynamic three-dimensional culture on osteogenic potential of human periodontal ligament-derived mesenchymal stem cells entrapped in alginate microbeads.

Journal of periodontal research·2014
Same author

Substantivity of sunscreens: an appraisal of some quaternary ammonium sunscreens.

International journal of cosmetic science·2009
Same author

Aripiprazole for schizophrenia. Systematic review.

The British journal of psychiatry : the journal of mental science·2006
Same author

Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia.

The Cochrane database of systematic reviews·2006
Same author

Aripiprazole for schizophrenia.

The Cochrane database of systematic reviews·2004
Same author

Return to play after cervical spine injury.

Spine·2001

Area of Science:

  • Psychiatry and Pharmacology
  • Clinical Trial Analysis
  • Schizophrenia Treatment Research

Background:

  • Typical antipsychotics for schizophrenia present challenges, including treatment resistance and adverse effects.
  • Aripiprazole, an atypical antipsychotic, is investigated for its efficacy and safety profile.

Purpose of the Study:

  • To evaluate the clinical effectiveness of aripiprazole in patients with schizophrenia and schizophrenia-like psychoses.
  • To compare aripiprazole against placebo, typical, and other atypical antipsychotic medications.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) identified through comprehensive database searches.
  • Data extraction and analysis focused on efficacy, tolerability, and adverse events, employing intention-to-treat principles.

Related Experiment Videos

  • Included 15 RCTs with 7110 participants, with an updated search identifying 5 additional papers.

    • Main Results:

    • Aripiprazole significantly reduced relapse rates and improved treatment adherence compared to placebo.
    • Compared to typical antipsychotics, aripiprazole showed no significant differences in global state or quality of life, but reduced akathisia and antiparkinsonian medication needs.
    • Against other atypical antipsychotics (olanzapine, risperidone), aripiprazole demonstrated similar efficacy but potentially lower prolactin elevation and QTc interval prolongation.

    Conclusions:

    • Aripiprazole demonstrates efficacy in schizophrenia treatment, comparable to existing typical and atypical antipsychotics.
    • It may offer a reduced risk of akathisia versus typical agents and lower prolactin and QTc prolongation versus some atypical agents.
    • Further well-reported, pragmatic RCTs are needed to establish aripiprazole's definitive role in clinical practice.